Similarly, co-treatment with the HOTAIR-EZH2 inhibitor AC1Q3QWB and the CDK4/6 inhibitor palbociclib has been shown to modulate cell cycle and Wnt/β-catenin signaling, curbing GBM cell progression and migration [301]. Here, CDK4 is linked to glioblastoma.